For more than a decade, drug shortages, particularly of sterile injectables, and other essential hospital medicines—have strained the US healthcare system and exposed deep structural weaknesses in the pharmaceutical supply chain. In response, policymakers, hospital systems, and industry leaders have increasingly turned to FDA-registered outsourcing facilities, commonly referred to as 503B compounding facilities, as a potential mitigation mechanism.